Today: 7 February 2026
Subscribe

Mateusz Kaczmarek

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

AI Chip Frenzy Sends Lam Research Soaring 117% – More Upside Ahead?

AI Chip Frenzy Sends Lam Research Soaring 117% – More Upside Ahead?

Lam Research Rides the AI Wave to New Highs Lam Research, a leading maker of semiconductor fabrication equipment, has been one of 2025’s standout stocks. The company’s share price has more than doubled this year, up about 117% as of early Novembernasdaq.com. This surge has far outpaced even the high-flying AI chip designers: for comparison, Nvidia’s stock was up ~42% and Broadcom’s ~56% over the same periodsharewise.com. Lam’s stock recently notched a fresh record high around $157–$158 per sharenasdaq.comstockstory.org, boosting the company’s market capitalization to roughly $195 billionstockstory.org. The run-up reflects surging optimism that Lam will be a prime beneficiary of
3 November 2025
··
Axsome Therapeutics (AXSM) Skyrockets on CNS Breakthroughs: Stock Surge, Pipeline Wins, and 2025 Outlook

Axsome Therapeutics (AXSM) Skyrockets on CNS Breakthroughs: Stock Surge, Pipeline Wins, and 2025 Outlook

Stock Performance and Recent Trend Axsome’s stock has been a standout performer in 2025. As of November 3, 2025, AXSM trades around $134–$135 per share, roughly doubling from its 52-week low of $75.56 Finviz. The stock has gained about 60% year-to-date and 52% over the past year Seattlepi – a remarkable run that far outpaces the broader biotech sector and the S&P 500. This surge reflects growing investor optimism as Axsome transforms into a commercial-stage company with multiple marketed drugs. Recent trading momentum: In the days leading up to Nov 3, AXSM shares climbed steadily, likely in anticipation of strong
3 November 2025
ClearPoint Neuro (CLPT) Stock Skyrockets on Brain Therapy Breakthroughs – 2025 Deep Dive

ClearPoint Neuro (CLPT) Stock Skyrockets on Brain Therapy Breakthroughs – 2025 Deep Dive

Stock Performance & Trading Trends (2025) ClearPoint Neuro’s stock has delivered dramatic gains in 2025, transforming from a little-known small-cap into a high-flyer. The share price rallied over 300% from 2024 lows, driven by positive news in both the company’s own product line and its partners’ clinical trial successes. Notably, CLPT climbed from roughly $5.50 in May 2024 to over $19 by February 2025nasdaq.com. After a mid-year breather, momentum returned in Q3/Q4 2025: the stock surged nearly 40% in one day on September 24, 2025 after announcing an FDA clearance (for its Prism laser) and bullish revenue guidancenasdaq.comnasdaq.com. By late
3 November 2025
·
Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Analyst outlook & forecast: Long-term, analysts model robust growth. For example, one financial model projects ~18% revenue CAGR: ~$3.3 billion in sales by 2028 and ~$261 million net incomesimplywall.st. Another estimate sees revenue rising from ~$2.35 B in 2025 to ~$3.34 B by 2027tipranks.com, and free cash flow turning positive in 2025simplywall.st. These forecasts assume continued momentum in weight-loss/metabolic services plus gains in new verticals. Yet many investors note the high valuation (HIMS trades near ~$45 with market cap in the billions) and regulatory/legal risks. Community “fair value” estimates vary widely (some as low as $41) due to uncertaintysimplywall.st. Key analysts (TD Cowen, KeyBanc) maintain
3 November 2025
···
CURE Pharmaceutical (CURR) Stock Skyrockets Amid Wellness Pivot – What’s Next for Investors?

CURE Pharmaceutical (CURR) Stock Skyrockets Amid Wellness Pivot – What’s Next for Investors?

High-Flying Share Price and Recent Performance 🚀 As of November 3, 2025, CURE Pharmaceutical’s stock is trading around $3.6 per share, reflecting an explosive rise in late October. On Friday, Oct 31, the stock closed at $3.78, up from $2.89 the day priorstockinvest.us. That single-day gain of +30.8% crowned CURR (now AVRW) as one of the market’s top percentage gainers. In fact, the stock has rallied five days in a row, more than doubling (+104% in two weeks) amid surging volumestockinvest.us. This momentum continued into Nov 3, with an opening trade around $3.52 and only a modest pullback from last
3 November 2025
·
Nocera (NCRA) Stock Skyrockets 36% on $300M Digital Asset Deal – Key Facts & Outlook

Nocera (NCRA) Stock Skyrockets 36% on $300M Digital Asset Deal – Key Facts & Outlook

Company Overview and Business Model Nocera is a small-cap company that began in the aquaculture technology niche. It designs and builds land-based recirculating aquaculture systems (RAS) – essentially the tanks, filtration equipment, and engineering needed for sustainable fish farmsstockanalysis.com. Founded in 2014 and based in New Taipei City, Taiwan, Nocera provided engineering, procurement, and construction services to fish farming projects, aiming to make seafood production more efficient on landstockanalysis.com. In 2023–2024, Nocera branded itself as a “fully integrated sustainable seafood company,” but it has since broadened its scope. Now the firm calls itself “dynamic, industry-agnostic, and acquisition-focused,” seeking to acquire
3 November 2025
·
TG Therapeutics Stock Soars on Briumvi Boom – Key Facts, Analyst Insights & 2025 Outlook

TG Therapeutics Stock Soars on Briumvi Boom – Key Facts, Analyst Insights & 2025 Outlook

Company Overview: Briumvi-Focused Business Model TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in treatments for B-cell mediated diseasesgurufocus.com. After years as a development-stage biotech, TG entered the commercial arena with Briumvi, its first approved product, and now generates the majority of revenue from Briumvi sales in the U.S.gurufocus.com. The company’s strategy centers on leveraging its expertise in B-cell biology to address both autoimmune disorders and B-cell cancers. Briumvi – A Breakthrough in Multiple Sclerosis Therapy Briumvi (ublituximab-xiiy) is TG’s flagship drug, approved by the FDA in December 2022 for adults with relapsing forms of multiple sclerosis (RMS)ir.tgtherapeutics.com. It
3 November 2025
Dominion Energy’s Q3 Shocker: Data Center Boom and Offshore Wind Pay Off in Surging Profits

Dominion Energy’s Q3 Shocker: Data Center Boom and Offshore Wind Pay Off in Surging Profits

Dominion Delivers an Earnings Beat in Q3 2025 Dominion Energy turned in strong third-quarter 2025 results, surpassing analyst expectations on the bottom line. The utility reported net income of $1.0 billion for Q3 (about $1.16 per share), up from $934 million ($1.09) in the same quarter a year agonews.dominionenergy.com. On an operating basis (excluding one-time items), earnings were $921 million, or $1.06 per share, comfortably beating consensus estimates in the mid-$0.90s rangenews.dominionenergy.comreuters.com. This performance marked roughly an 8% increase in per-share earnings year-over-year – a notable achievement for a regulated utility. Revenue also leapt 14.9% to $4.53 billion from $3.94 billion in Q3 2024investing.com, reflecting
3 November 2025
··
Biohaven Stock’s Wild Ride: Big Drops, Big Hopes as FDA Verdict Nears

Biohaven Stock’s Wild Ride: Big Drops, Big Hopes as FDA Verdict Nears

In summary, Biohaven’s stock is a tale of high stakes in biotech. Recent price swings underscore the uncertainty, but also the potential reward if Biohaven’s bets pay off. With an FDA verdict looming and multiple shots on goal in its pipeline, investors should brace for more turbulence. The company’s strong institutional backing and “Strong Buy” analyst consensus indicate confidence in the science Investing Directorstalkinterviews. Still, caution is warranted – Biohaven will need to deliver clinical and regulatory wins to justify those bullish forecasts. In the coming weeks, news flow (FDA decision, earnings, trial readouts) could rapidly shift the narrative yet
3 November 2025
·
Iovance Biotherapeutics (IOVA): TIL Cancer Breakthrough or Biotech Bust?

Iovance Biotherapeutics (IOVA): TIL Cancer Breakthrough or Biotech Bust?

Company Overview: Pioneering TIL Therapy in Oncology Iovance Biotherapeutics is focused on developing tumor-infiltrating lymphocyte (TIL) therapies – a novel form of immunotherapy where a patient’s own T cells, harvested from their tumor, are expanded and activated in a lab, then reinfused to attack cancer. This approach, originally pioneered by NCI’s Dr. Steven Rosenberg in the 1980s, finally reached fruition when Iovance’s lifileucel (brand name Amtagvi) earned FDA approval in 2024 as the first-ever TIL therapy (and the first cellular therapy for any solid tumor)cancer.gov. Lifileucel is indicated for unresectable or metastatic melanoma that has progressed after standard immunotherapies (e.g.
3 November 2025
Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Company Background and Business Model Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company specializing in RNA interference (RNAi) therapies for cancer. The company was co-founded by Nobel laureate Dr. Craig Mello, a discoverer of RNAi, leveraging that legacy to develop its proprietary INTASYL™ gene-silencing technologyphiopharma.com. Originally known as RXi Pharmaceuticals (founded ~2011), Phio rebranded and refocused on immuno-oncology. Its mission is to use small interfering RNA (siRNA) to “silence” genes that allow tumors to evade the immune system, thereby empowering the body’s own defenses to fight cancerragingbull.com. Headquartered in Pennsylvania (King of Prussia) with R&D roots in Massachusetts, Phio is
3 November 2025
··
ON Semiconductor (ON) Stock Surges on Q3 Earnings Beat – Latest News, Financials, and Outlook

ON Semiconductor (ON) Stock Surges on Q3 Earnings Beat – Latest News, Financials, and Outlook

Recent News and Updates (Early November 2025) Earnings Release: On November 3, 2025, ON Semiconductor announced its third-quarter 2025 financial results, which were better than expected. The company reported Q3 revenue of $1.55 billion (down roughly 11% year-over-year) and a profit of $255 million Timesunion Timesunion. Earnings came out to $0.63 per diluted share, beating Wall Street’s consensus of $0.60. This marks a positive surprise given the headwinds the company faced earlier in the year. Management noted that the results “exceeded expectations, underscoring the strength of our strategy and the resilience of our business model,” according to CEO Hassane El-Khoury Tradingview. He
3 November 2025
··
UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

Stock Performance: Skyrockets and Crashes UniQure’s stock has been on a wild ride in 2025. After starting the year in the mid-teens, QURE shares skyrocketed through mid-2025 on hopes for its Huntington’s gene therapy. The rally hit a fever pitch in late September when Phase 1/2 trial data showed a remarkable 75% reduction in disease progression with AMT-130 – news that caused the stock to surge almost 200% that monthreuters.com. By late October, QURE was hovering around $68–$70, up roughly 300–500% from spring levels. However, in the past few days the stock’s momentum sharply reversed. On Monday, Nov 3, 2025,
3 November 2025
·
MongoDB’s CEO Shake-Up: 11-Year Veteran Departs as Cloudflare Exec Takes Charge Amid Stock Surge

MongoDB’s CEO Shake-Up: 11-Year Veteran Departs as Cloudflare Exec Takes Charge Amid Stock Surge

Leadership Transition at MongoDB MongoDB’s announcement on November 3, 2025 signaled a major leadership shake-up for the $29 billion database company. Dev Ittycheria, who has served as CEO since 2014, will be stepping down after an 11-year tenure leading MongoDBmarkets.ft.com. Ittycheria is credited with transforming MongoDB from a startup into a global player – he oversaw the company’s 2017 IPO and the growth of its customer base to nearly 60,000 organizations (including over 75% of the Fortune 100)markets.ft.cominvesting.com. In the press release, Ittycheria called it “the privilege of a lifetime to lead MongoDB” and said he is “immensely grateful to our
3 November 2025
··
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Stock Price and Recent Performance Pfizer’s stock has languished in 2025 despite a rising broader market. At ~$24.65, PFE is roughly flat since January and far below its 2021 peak (~$50)sharewise.com. In the past three years, the shares have tumbled about 50% as the company’s COVID-fueled revenue boom faded and investors braced for patent expirationssharewise.com. By mid-2025, Pfizer traded near multi-year lows (around $23), though it bounced off those lows in early October after positive news on earnings and policy. Notably, Pfizer’s stock surged ~15% at the end of Q3 (from ~$23.85 on Sept. 29 to ~$27.37 by Oct. 3statmuse.comstatmuse.com)
3 November 2025
·
Amazon Stock Skyrockets to Record High on AWS Boom – Analysts Predict More Upside

Amazon Stock Skyrockets to Record High on AWS Boom – Analysts Predict More Upside

Amazon Stock Price: Record High After Earnings Surge Amazon’s stock is riding high after its latest earnings triumph. Shares of AMZN skyrocketed ~10% on Friday, Oct. 31 following the Q3 report, pushing the stock to an all-time high in the mid-$240s per sharereuters.com. That one-day pop – Amazon’s biggest in years – added roughly $200 billion to its market capitalization and lifted the stock’s year-to-date performance into double-digit gains. Prior to the earnings, Amazon had been a notable laggard among Big Tech peers in 2025 (up only ~1.6% YTD), but the post-earnings rally has “helped pull Amazon out of that
3 November 2025
··
Opendoor Stock Skyrockets 1300% Amid Meme Hype – Will the Rally Survive the Housing Slump?

Opendoor Stock Skyrockets 1300% Amid Meme Hype – Will the Rally Survive the Housing Slump?

The 1300% Rally and Meme Stock Frenzy Opendoor’s stock has experienced a jaw-dropping rally in 2025, transforming from a penny-stock into a retail trading sensation. After languishing below $1 per share through mid-year (and drawing a Nasdaq delisting warning), OPEN caught fire over the summer. A coalition of individual investors on Reddit and X (formerly Twitter) began touting Opendoor as the next big “meme stock,” similar to past hits like GameStop and AMCnasdaq.com. This social-media enthusiasm, combined with activist investor pressure, ignited a massive short squeeze and sent Opendoor shares rocketing up around 1,300% from their lowsnasdaq.com. The stock exploded
3 November 2025
·
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Company Overview and Background Acrivon Therapeutics is a Boston-area biotech (NASDAQ: ACRV) founded in 2018, emerging with a mission to revolutionize cancer treatment through precision medicinestockanalysis.com. The company’s name “Acrivon” is derived from “accurate” or “precision,” reflecting its core approach: develop targeted oncology drugs hand-in-hand with diagnostics that pinpoint the patients who will respond. Acrivon’s proprietary platform, AP3 (Acrivon Predictive Precision Proteomics), lies at the heart of this strategy. Using proteomics and AI tools, AP3 measures the activity of myriad proteins and signaling pathways inside tumor cells in their native state, rather than just analyzing DNA mutationsglobenewswire.comglobenewswire.com. This allows Acrivon
3 November 2025
·
NIO Stock Skyrockets on Record Sales and Bold Moves – Can the Rally Last?

NIO Stock Skyrockets on Record Sales and Bold Moves – Can the Rally Last?

NIO Stock Performance: Latest Price and Short-Term Trend NIO’s stock has been on a notable upswing heading into November 2025. Shares closed at $7.25 on October 31, 2025 – a multi-month high – after jumping over 3% in a single day following the latest delivery reportstockinvest.us. This capped a strong week; NIO gained roughly 5.1% over the last week of October, even though it was still down a few percent over the full monthsimplywall.st. The late-October bounce reflects renewed investor enthusiasm around the company’s record sales figures and growth trajectory. It’s worth noting that NIO’s current price around $7+ represents
3 November 2025
·
TGE Stock’s Wild Ride: Why The Generation Essentials Group Is Making Headlines in Nov 2025

TGE Stock’s Wild Ride: Why The Generation Essentials Group Is Making Headlines in Nov 2025

Recent Stock Performance and Volatility (Late Oct – Early Nov 2025) TGE’s stock has experienced a rollercoaster in recent days, capturing investors’ attention. In the final week of October 2025, shares entered a freefall: between October 27 and October 31 the price plunged from highs near $1.89 to a low of $0.7777 intraday on Oct 31 Stockstotrade. The October 31 session was especially dramatic – TGE opened around $1.79 but collapsed over 50%, hitting that record low of $0.78 before closing at $1.01 Stockstotrade Stockstotrade. This marked a single-day drop of ~54%, capping a multi-day slide in which the stock
3 November 2025
·
1 … 48 49 50 51 52 … 140

Stock Market Today

Meta stock ends week down about 6% as Wall Street fixates on $135 billion AI capex

Meta stock ends week down about 6% as Wall Street fixates on $135 billion AI capex

7 February 2026
New York, February 7, 2026, 09:54 EST — Market closed. Meta Platforms closed down 1.3% on Friday at $661.46 and was last up 0.4% in after-hours trade at $664.00. The stock finished the week down about 6.4%. (Investing.com) The pullback matters because investors are no longer treating Big Tech’s artificial-intelligence buildout as a free lunch. Alphabet, Microsoft, Amazon and Meta are expected to spend more than $630 billion combined this year, and Meta has projected up to $135 billion in capital expenditures — money for long-lived assets such as data centers and servers. (Reuters) That spending binge has become the
CleanSpark stock price jumps 22% after earnings and AI push — what CLSK traders watch next week

CleanSpark stock price jumps 22% after earnings and AI push — what CLSK traders watch next week

7 February 2026
CleanSpark shares jumped 22% to $10.08 Friday after quarterly results and an AI infrastructure update, following bitcoin’s rebound above $70,000. The company reported a quarterly net loss tied to bitcoin price swings and outlined plans to expand power capacity in Houston. Peers Marathon Digital and Riot Platforms also surged. Upcoming U.S. jobs and inflation data next week could add further volatility.
Go toTop